Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders: a Scoping Review
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders : a Scoping Review. / Møller, Christian; Miskowiak, Kamilla W.; Kessing, Lars Vedel; Vinberg, Maj.
In: Current Treatment Options in Psychiatry, Vol. 9, No. 2, 2022, p. 55-72.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders
T2 - a Scoping Review
AU - Møller, Christian
AU - Miskowiak, Kamilla W.
AU - Kessing, Lars Vedel
AU - Vinberg, Maj
N1 - Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2022
Y1 - 2022
N2 - Purpose: First-degree relatives of patients with bipolar disorder (BD) or major depressive disorder (MDD) are at risk of developing a major psychiatric disorder. However, preventive studies using pharmacological treatment of this high-risk group are sparse. The present study undertakes a scoping review to evaluate the literature of pharmacological treatment of individuals at familial risk of BP or MDD. Recent findings: Previous reviews on the pharmacological treatment of first-degree relatives at risk of BD, primarily investigates high-risk participants who were offspring of parents with BD and to our knowledge have not included individuals at risk of MDD, although it is well-known that there is a genetic overlap between BD and MDD. Summary: Nine studies comprising 299 high-risk individuals, mainly adolescents, were included. Aripiprazole, lithium, paroxetine, divalproex, quetiapine, lamictal, and escitalopram were investigated. One study only detected a positive effect, reducing mania symptoms, a study on aripiprazole vs placebo. Five planned or ongoing studies were identified. Only one study is still recruiting and the others either terminated due to recruitment difficulties or passed their marked completion date. Recruitment difficulties seem to be a major challenge; however, adult individuals at high risk are not well investigated and would presumably be easier to recruit. It is not clear if pharmacological interventions may prevent the onset of mood disorders, and further research is warranted.
AB - Purpose: First-degree relatives of patients with bipolar disorder (BD) or major depressive disorder (MDD) are at risk of developing a major psychiatric disorder. However, preventive studies using pharmacological treatment of this high-risk group are sparse. The present study undertakes a scoping review to evaluate the literature of pharmacological treatment of individuals at familial risk of BP or MDD. Recent findings: Previous reviews on the pharmacological treatment of first-degree relatives at risk of BD, primarily investigates high-risk participants who were offspring of parents with BD and to our knowledge have not included individuals at risk of MDD, although it is well-known that there is a genetic overlap between BD and MDD. Summary: Nine studies comprising 299 high-risk individuals, mainly adolescents, were included. Aripiprazole, lithium, paroxetine, divalproex, quetiapine, lamictal, and escitalopram were investigated. One study only detected a positive effect, reducing mania symptoms, a study on aripiprazole vs placebo. Five planned or ongoing studies were identified. Only one study is still recruiting and the others either terminated due to recruitment difficulties or passed their marked completion date. Recruitment difficulties seem to be a major challenge; however, adult individuals at high risk are not well investigated and would presumably be easier to recruit. It is not clear if pharmacological interventions may prevent the onset of mood disorders, and further research is warranted.
KW - Bipolar disorder
KW - Family
KW - Major Depressive disorder
KW - Pharmacological treatment
KW - Risk factors
U2 - 10.1007/s40501-022-00258-2
DO - 10.1007/s40501-022-00258-2
M3 - Journal article
AN - SCOPUS:85127587042
VL - 9
SP - 55
EP - 72
JO - Current Treatment Options in Psychiatry
JF - Current Treatment Options in Psychiatry
SN - 2196-3061
IS - 2
ER -
ID: 308119581